Our platforms: amyloid preparation, bioassays & medicinal chemistry

The competitive position of Senexis relies on the barriers to entry provided by its intellectual property rights and know-how in the areas of amyloid preparation and biochemistry, assay development, medicinal chemistry, amyloid pathology and clinical development.  In particular, the broad and defensible portfolio of “composition-of-matter” patents protects a series of compounds that inhibit the misfolding, aggregation and associated toxicity of amyloid-forming proteins. The portfolio of compounds comprises novel molecules generated by the Company’s proprietary assay platforms and discovery tools, along with in-licensed compounds that Senexis has continued to develop further. This approach provides multiple product opportunities for potentially treating all diseases of amyloid-related toxicity derived from an efficient and cost-effective discovery platform.

Senexis operates on a “semi-virtual” basis, in which only the preparation of toxic forms of amyloid and the proprietary core in vitro assays are run internally.  The Company has been established in a self-contained small operational base of 1,700 square feet in the Bioincubator Building on the Babraham Research Campus in Cambridge since June 2004. Medicinal Chemistry, DMPK and some of our efficacy testing of our novel molecules are carried out through collaborations with contract research organisations and academic groups. The Company's registered office is located at Babraham Hall on the Campus, a photograph of which is shown to the right.